Action CTMX CYTOMX THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues CytomX Therapeutics, Inc.

Actions

CTMX

US23284F1057

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 10/06/2024 		Varia. 5j. Varia. 1 janv.
1,63 USD -0,61 % Graphique intraday de CytomX Therapeutics, Inc. -6,86 % +5,16 %
28/05 CYTOMX THERAPEUTICS, INC. : Piper Sandler passe de neutre à achat ZM
09/05 CYTOMX THERAPEUTICS, INC. : BMO Capital neutre sur le dossier ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
CytomX Therapeutics Announces New Employment Inducement Grants
CytomX Therapeutics : Definitive Additional Materials
CytomX Therapeutics : Annual Meeting Rules of Conduct
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904
CytomX Therapeutics : First Quarter Earnings Update - May 8, 2024
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M
CytomX Therapeutics: Q1 Earnings Snapshot
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
CytomX Therapeutics : 2023 Annual Report
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CTMX
  4. Actualités CytomX Therapeutics, Inc.
  5. Autres langues